Prof. Beat Thürlimann - Kontakt Titel Vorname Nachname Strasse Stadt Land Telefonnummer - Research KSSG
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Prof. Beat Thürlimann Kontakt Titel Prof. Dr. Vorname Beat Nachname Thürlimann Strasse Rorschacherstrasse 95 Stadt 9007 St.Gallen Land Switzerland Telefonnummer ++41 71 494 20 73 E-Mail beat.thuerlimann@kssg.ch Webseite www.kssg.ch/brustzentrum
Forschungsprofil
Akademischer Status
Departement Interdisziplinäre Medizinische Dienste
Abteilung Senologie-Zentrum Ostschweiz
2Publikationen
Titel
Wissensch- Burstein H J, Curigliano G, Thürlimann B, Weber W P, Poortmans P, Regan
aftlicher M M, Senn H J, Winer E P, Gnant M, Panelists of the St Gallen Consensus
Artikel/ Conference . Customizing local and systemic therapies for women with
Review early breast cancer: the St. Gallen International Consensus Guidelines for
treatment of early breast cancer 2021. Ann Oncol 2021;.
Stoffel S T, von Moos R, Thürlimann B, Cathomas R, Gillessen S, Zürrer-
Härdi U, von Briel T, Anchisi S, Feller A, Schär C, Dietrich D,
Schwenkglenks M, Lupatsch J E, Mark M T. Patterns of care and economic
consequences of using bone-targeted agents for castration-sensitive
prostate cancer patients with bone metastases to prevent skeletal-related
events in Switzerland - the SAKK 95/16 prostate study. Swiss Med Wkly
2021; 151:w20464.
Herrmann C, Morant R, Walser E, Mousavi M, Thürlimann B. Screening is
associated with lower mastectomy rates in eastern Switzerland beyond
stage effects. BMC Cancer 2021; 21:229.
Ribi K, Thürlimann B, Schär C, Dietrich D, Cathomas R, Zürrer-Härdi U,
von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart M,
Caspar C B, von Moos R, Mark M. Quality of life and pain in patients with
metastatic bone disease from solid tumors treated with bone-targeted
agents- a real-world cross-sectional study from Switzerland (SAKK
95/16). BMC Cancer 2021; 21:182.
Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle D A,
Rothgiesser K, Pagani O, Thürlimann B. Plasma HER2ECD a promising
test for patient prognosis and prediction of response in HER2 positive
breast cancer: results of a randomized study - SAKK 22/99. BMC Cancer
2020; 20:114.
3Publikationen
Titel
Wissensch- Maranta A F, Broder S, fritzsche c, knauer m, Thürlimann B, Jochum W,
aftlicher ruhstaller t. Do YOU know the Ki-67 index of your breast cancer patients?
Artikel/ Knowledge of your institution's Ki-67 index distribution and its robustness
Review is essential for decision-making in early breast cancer. Breast 2020;
51:120-126.
Luen S J, Asher R, Lee C K, Savas P, Kammler R, Dell'orto P, Biasi O M,
Demanse D, Hackl W, Thürlimann B, Viale G, Di Leo A, Colleoni M, Regan
M M, Loi S. Identifying oncogenic drivers associated with increased risk of
late distant recurrence in postmenopausal, estrogen receptor-positive,
HER2-negative early breast cancer: results from the BIG 1-98 study. Ann
Oncol 2020; 31:1359-1365.
Rabaglio M, Sun Z, Maibach R, Giobbie-Hurder A, Ejlertsen B, Harvey V J,
Neven P, Láng I, Bonnefoi H, Wardley A, Ruepp B, Castiglione M, Coates
A S, Gelber R D, Goldhirsch A, Colleoni M, Thürlimann B, Regan M M.
Cumulative incidence of cardiovascular events under tamoxifen and
letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast
Cancer Res Treat 2020;.
Leone J P, Cole B F, Regan M M, Thürlimann B, Coates A S, Rabaglio M,
Giobbie-Hurder A, Gelber R D, Ejlertsen B, Harvey V J, Neven P, Láng I,
Bonnefoi H, Wardley A, Goldhirsch A, Di Leo A, Colleoni M, Vaz-Luis I, Lin
N U. Clinical behavior of recurrent hormone receptor-positive breast
cancer by adjuvant endocrine therapy within the Breast International
Group 1-98 clinical trial. Cancer 2020;.
Kensler K H, Regan M M, Heng Y J, Baker G M, Pyle M E, Schnitt S J,
Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi
R M. Prognostic and predictive value of androgen receptor expression in
postmenopausal women with estrogen receptor-positive breast cancer:
results from the Breast International Group Trial 1-98. Breast Cancer Res
2019; 21:30.
4Publikationen
Titel
Wissensch- Denkert C, Budczies J, Regan M M, Loibl S, Dell'Orto P, von Minckwitz G,
aftlicher Mastropasqua M G, Solbach C, Thürlimann B, Mehta K, Blohmer J U,
Artikel/ Colleoni M, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R,
Review Pfitzner B M, Dietel M, Fasching P A, Viale G. Clinical and analytical
validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and
GeparTrio trial: systematic modulation of interobserver variance in a
comprehensive in silico ring trial. Breast Cancer Res Treat 2019;
176:557-568.
schmid s, Klingbiel D, Aebi S, Goldhirsch A, Mamot C, Munzone E, Nolè F,
Oehlschlegel C, Pagani O, Pestalozzi B, Rochlitz C, Thürlimann B, von
Moos R, Weder P, Zaman K, ruhstaller t. Long-term responders to
trastuzumab monotherapy in first-line HER-2+ advanced breast cancer:
characteristics and survival data. BMC Cancer 2019; 19:902.
Varga Z, Li Q, Jochum W, Perriard U, Rau T, Tille J C, Hawle H, Klingbiel
D, Thürlimann B, Ruhstaller T. Ki-67 assessment in early breast cancer:
SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci
Rep 2019; 9:13534.
Burstein H J, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P,
Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn H J, Winer E P,
Thürlimann B, Members of the St. Gallen International Consensus Panel
on the Primary Therapy of Early Breast Cancer 2019 . Estimating the
benefits of therapy for early-stage breast cancer: the St. Gallen
International Consensus Guidelines for the primary therapy of early
breast cancer 2019. Ann Oncol 2019; 30:1541-1557.
5Publikationen
Titel
Wissensch- Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S,
aftlicher Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, Panel
Artikel/ Members of the St. Gallen International Expert Consensus on the Primary
Review Therapy of Early Breast Cancer 2017 . De-escalating and escalating
treatments for early-stage breast cancer: the St. Gallen International
Expert Consensus Conference on the Primary Therapy of Early Breast
Cancer 2017. Ann Oncol 2019; 30:1181.
Burstein H J, Curigliano G, Loibl S, Dubsky P, Gnant M, Poortmans P,
Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn H J, Winer E P,
Thürlimann B, Members of the St. Gallen International Consensus Panel
on the Primary Therapy of Early Breast Cancer 2019 . Estimating the
benefits of therapy for early-stage breast cancer: the St. Gallen
International Consensus Guidelines for the primary therapy of early
breast cancer 2019. Ann Oncol 2019; 30:1541-1557.
Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S,
Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, Panel
Members of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer 2017 . Corrections to "De-escalating and
escalating treatments for early-stage breast cancer: the St. Gallen
International Expert Consensus Conference on the Primary Therapy of
Early Breast Cancer 2017". Ann Oncol 2019; 30:1181.
Coates A S, Goldhirsch A, Gelber R D, Ingle J N, Thürlimann B, Senn H J.
Reply to Does the expert panel at the St Gallen meeting provide an
unbiased opinion about the management of women with early breast
cancer?. Ann Oncol 2019; 20:1751-1752.
6Publikationen
Titel
Wissensch- Mark M, Thürlimann B, Ribi K, Schär C, Dietrich D, Cathomas R, Zürrer-
aftlicher Härdi U, von Briel T, Anchisi S, Bohanes P, Blum V, von Burg P, Mannhart
Artikel/ M, Caspar C B, von Moos R. Patterns of care for patients with metastatic
Review bone disease in solid tumors: A cross-sectional study from Switzerland
(SAKK 95/16). J Bone Oncol 2019; 21:100273.
Buechler S A, Gray K P, Gökmen-Polar Y, Willis S, Thürlimann B, Kammler
R, Viale G, Leyland-Jones B, Badve S S, Regan M M. Independent
Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-
Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant
Endocrine Therapy for Postmenopausal Women With Hormone Receptor-
Positive, Early Breast Cancer. JNCI Cancer Spectr 2019; 3:pkz051.
ruhstaller t, Giobbie-Hurder A, Colleoni M, Jensen M B, Ejlertsen B, de
Azambuja E, Neven P, Láng I, Jakobsen E H, Gladieff L, Bonnefoi H,
Harvey V J, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E,
Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di
Leo A, Gelber R D, Coates A S, Goldhirsch A, Thürlimann B, Regan M M,
members of the BIG 1-98 Collaborative Group and the International
Breast Cancer Study Group . Adjuvant Letrozole and Tamoxifen Alone or
Sequentially for Postmenopausal Women With Hormone Receptor-Positive
Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol
2018;JCO1800440.
Luen S J, Asher R, Lee C K, Savas P, Kammler R, Dell'orto P, Biasi O M,
Demanse D, JeBailey L, Dolan S, Hackl W, Thürlimann B, Viale G, Colleoni
M, Regan M M, Loi S. Association of Somatic Driver Alterations With
Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative
Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized
Clinical Trial. JAMA Oncol 2018;.
7Publikationen
Titel
Wissensch- Herrmann C, Vounatsou P, Thürlimann B, Probst-Hensch N, Rothermundt
aftlicher C, Ess S. Impact of mammography screening programmes on breast
Artikel/ cancer mortality in Switzerland, a country with different regional
Review screening policies. BMJ Open 2018; 8:e017806.
Van Asten K, Slembrouck L, Olbrecht S, Jongen L, Brouckaert O, Wildiers
H, Floris G, Van Limbergen E, Weltens C, Smeets A, Paridaens R, Giobbie-
Hurder A, Regan M M, Viale G, Thürlimann B, Vergote I, Christodoulou E,
Van Calster B, Neven P. Prognostic Value of the Progesterone Receptor by
Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative
Breast Cancer. Oncologist 2018;.
Baumann M, Dani S U, Dietrich D, Hochstrasser A, Klingbiel D, Mark M T,
Riesen W F, ruhstaller t, Templeton A J, Thürlimann B. Vitamin D levels in
Swiss breast cancer survivors. Swiss Med Wkly 2018; 148:w14576.
Dowsett M, Sestak I, Regan M M, Dodson A, Viale G, Thürlimann B,
Colleoni M, Cuzick J. Integration of Clinical Variables for the Prediction of
Late Distant Recurrence in Patients With Estrogen Receptor-Positive
Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin
Oncol 2018; 36:1941-1948.
8Publikationen
Titel
Wissensch- Curigliano G, Burstein H J, Winer E P, Gnant M, Dubsky P, Loibl S,
aftlicher Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B,
Artikel/ André F, Baselga J, Bergh J, Bonnefoi H, Brucker S Y, Cardoso F, Carey L,
Review Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P,
Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D F,
Huang C S, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M,
Orecchia R, Osborne K C, Pagani O, Partridge A H, Pritchard K, Ro J,
Rutgers E J T, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A,
Viale G, Watanabe T, Whelan T J, Xu B. De-escalating and escalating
treatments for early-stage breast cancer: the St. Gallen International
Expert Consensus Conference on the Primary Therapy of Early Breast
Cancer 2017. Ann Oncol 2018; 29:2153.
Ess S M, Herrmann C, Bouchardy C, Neyroud I, Rapiti E, Konzelmann I,
Bordoni A, Ortelli L, Rohrmann S, Frick H, Mousavi M, Thürlimann B.
Impact of subtypes and comorbidities on breast cancer relapse and
survival in population-based studies. Breast 2018; 41:151-158.
Steger G, Lüftner D, Stöger H, Thürlimann B, Untch M. Management of
HER2-Positive Early Breast Cancer. Breast Care (Basel) 2018;
13:453-455.
Wapnir I L, Price K N, Anderson S J, Robidoux A, Martín M, Nortier J W R,
Paterson A H G, Rimawi M F, Láng I, Baena-Cañada J M, Thürlimann B,
Mamounas E P, Geyer C E, Gelber S, Coates A S, Gelber R D, Rastogi P,
Regan M M, Wolmark N, Aebi S, International Breast Cancer Study Group
, NRG Oncology, GEICAM Spanish Breast Cancer Group, BOOG Dutch
Breast Cancer Trialists' Group , Breast International Group . Efficacy of
Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional
Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin
Oncol 2018; 36:1073-1079.
9Publikationen
Titel
Wissensch- Klingbiel D, Thürlimann B, Brauchli P, von Moos R. Absence of Evidence is
aftlicher not Evidence of Absence: The Case of Non-Inferiority. Ann Oncol 2017;.
Artikel/
Review Curigliano G, Burstein H J, P Winer E, Gnant M, Dubsky P, Loibl S,
Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, ,
André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L,
Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P,
Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D F,
Huang C S, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow
M, Orecchia R, Osborne K C, Pagani O, Partridge A H, Pritchard K, Ro J,
Rutgers E J T, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A,
Viale G, Watanabe T, Whelan T J, Xu B. De-escalating and escalating
treatments for early-stage breast cancer: the St. Gallen International
Expert Consensus Conference on the Primary Therapy of Early Breast
Cancer 2017. Ann Oncol 2017; 28:1700-1712.
Curigliano G, Burstein H J, Winer E P, Gnant M, Dubsky P, Loibl S,
Colleoni M, Regan M M, Piccart-Gebhart M, Senn H J, Thürlimann B, ,
André F, Baselga J, Bergh J, Bonnefoi H, Brucker S Y, Cardoso F, Carey L,
Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P,
Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes D F,
Huang C S, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M,
Orecchia R, Osborne K C, Pagani O, Partridge A H, Pritchard K, Ro J,
Rutgers E J T, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A,
Viale G, Watanabe T, Whelan T J, Xu B. Reply to "The St. Gallen
International Expert Consensus on the Primary Therapy of Early Breast
Cancer 2017: the point of view of an International Panel of Experts in
Radiation Oncology" by Kirova et al. Ann Oncol 2017;.
10Publikationen
Titel
Wissensch- Bartlett J M S, Ahmed I, Regan M M, Sestak I, Mallon E A, Dell'orto P,
aftlicher Thürlimann B, Seynaeve C, Putter H, Van de Velde C J H, Brookes C L,
Artikel/ Forbes J F, Viale G, Cuzick J, Dowsett M, Rea D W, . HER2 status predicts
Review for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients
from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J
Cancer 2017; 79:129-138.
Zweifel M, Thürlimann B, Riniker S, weder p, von Moos R, Pagani O,
Bigler M, Rothgiesser K M, Pilop C, Hawle H, Brauchli P, Tapia C,
Schoenfeld W, Sessa C, . Phase I trial of the androgen receptor
modulator CR1447 in breast cancer patients. Endocr Connect 2017;
6:549-556.
Borgquist S, Giobbie-Hurder A, Ahern T P, Garber J E, Colleoni M, Láng I,
Debled M, Ejlertsen B, von Moos R, Smith I, Coates A S, Goldhirsch A,
Rabaglio M, Price K N, Gelber R D, Regan M M, Thürlimann B. Cholesterol,
Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the
BIG 1-98 Study. J Clin Oncol 2017; 35:1179-1188.
Warschkow R, gueller u, Tarantino I, cerny t, Schmied B, Thürlimann B,
Joerger M. Improved Survival After Primary Tumor Surgery in Metastatic
Breast Cancer: A Propensity-adjusted, Population-based SEER Trend
Analysis. Ann Surg 2016; 263:1188-98.
Colleoni M, Sun Z, Price K N, Karlsson P, Forbes J F, Thürlimann B, Gianni
L, Castiglione M, Gelber R D, Coates A S, Goldhirsch A. Annual Hazard
Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up:
Results From the International Breast Cancer Study Group Trials I to V. J
Clin Oncol 2016;.
Crombag M R B S, Joerger M, Thürlimann B, Schellens J H M, Beijnen J H,
Huitema A D R. Pharmacokinetics of Selected Anticancer Drugs in Elderly
Cancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8:.
11Publikationen
Titel
Wissensch- Colleoni M, Gray K P, Gelber S, Láng I, Thürlimann B, Gianni L, Abdi E A,
aftlicher Gomez H L, Linderholm B K, Puglisi F, Tondini C, Kralidis E, Eniu A,
Artikel/ Cagossi K, Rauch D, Chirgwin J, Gelber R D, Regan M M, Coates A S,
Review Price K N, Viale G, Goldhirsch A. Low-Dose Oral Cyclophosphamide and
Methotrexate Maintenance For Hormone Receptor-Negative Early Breast
Cancer: International Breast Cancer Study Group Trial 22-00. J Clin Oncol
2016;.
Warschkow R, cerny t, Schmied B, gueller u, Thürlimann B, Joerger M. A
population-based analysis of secondary malignancies in breast cancer
patients receiving breast reconstruction. Br J Cancer 2016; 115:80-4.
Chirgwin J H, Giobbie-Hurder A, Coates A S, Price K N, Ejlertsen B,
Debled M, Gelber R D, Goldhirsch A, Smith I, Rabaglio M, Forbes J F,
Neven P, Láng I, Colleoni M, Thürlimann B. Treatment Adherence and Its
Impact on Disease-Free Survival in the Breast International Group 1-98
Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol
2016; 34:2452-9.
Pagani O, Klingbiel D, ruhstaller t, Nolè F, Eppenberger S, Oehlschlegel C,
Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B,
Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos
R v, Zaman K, Goldhirsch A, . Do all patients with advanced HER2
positive breast cancer need upfront-chemo when receiving trastuzumab?
Randomized Phase III trial SAKK 22/99. Ann Oncol 2016;.
Senn H J, Thürlimann B, Gnant M. St.Gallen-2015 in Vienna: News from
a successful breast cancer conference transposition!. Breast 2015;.
12Publikationen
Titel
Wissensch- Munzone E, Giobbie-Hurder A, Gusterson B A, Mallon E, Viale G,
aftlicher Thürlimann B, Ejlertsen B, Macgrogan G, Bibeau F, Lelkaitis G, Price K N,
Artikel/ Gelber R D, Coates A S, Goldhirsch A, Colleoni M, International Breast
Review Cancer Study Group and the BIG 1-98 Collaborative Group . Outcomes of
special histotypes of breast cancer after adjuvant endocrine therapy with
letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
Ann Oncol 2015;.
Herrmann C, Ess S, Thürlimann B, Probst-Hensch N, Vounatsou P.
40 years of progress in female cancer death risk: a Bayesian spatio-
temporal mapping analysis in Switzerland. BMC Cancer 2015; 15:666.
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D,
Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso M
J, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E,
Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove
C, Macgrogan G, Michiels S, Negreiros I, Offersen B V, Penault Llorca F,
Pruneri G, Roche H, Russell N S, Schmitt F, Servent V, Thürlimann B,
Untch M, van der Hage J A, van Tienhoven G, Wildiers H, Yarnold J,
Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli T S.
Guidelines for time-to-event end point definitions in breast cancer trials:
results of the DATECAN initiative (Definition for the Assessment of Time-
to-event Endpoints in CANcer trials)†. Ann Oncol 2015; 26:873-9.
Metzger Filho O, Giobbie-Hurder A, Mallon E, Gusterson B, Viale G, Winer
E P, Thürlimann B, Gelber R D, Colleoni M, Ejlertsen B, Debled M, Price K
N, Regan M M, Coates A S, Goldhirsch A. Relative Effectiveness of
Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma
in the BIG 1-98 Trial. J Clin Oncol 2015; 33:2772-9.
13Publikationen
Titel
Wissensch- Varga Z, Cassoly E, Li Q, oehlschlegel c, Tapia C, Lehr H A, Klingbiel D,
aftlicher Thürlimann B, ruhstaller t. Standardization for Ki-67 assessment in
Artikel/ moderately differentiated breast cancer. A retrospective analysis of the
Review SAKK 28/12 study. PLoS ONE 2015; 10:e0123435.
Gourgou-Bourgade S, Cameron D, Poortmans P, Asselain B, Azria D,
Cardoso F, A'Hern R, Bliss J, Bogaerts J, Bonnefoi H, Brain E, Cardoso M
J, Chibaudel B, Coleman R, Cufer T, Dal Lago L, Dalenc F, De Azambuja E,
Debled M, Delaloge S, Filleron T, Gligorov J, Gutowski M, Jacot W, Kirkove
C, Macgrogan G, Michiels S, Negreiros I, Offersen B V, Penault Llorca F,
Pruneri G, Roche H, Russell N S, Schmitt F, Servent V, Thürlimann B,
Untch M, van der Hage J A, van Tienhoven G, Wildiers H, Yarnold J,
Bonnetain F, Mathoulin-Pélissier S, Bellera C, Dabakuyo-Yonli T S.
Guidelines for time-to-event end point definitions in breast cancer trials:
results of the DATECAN initiative (Definition for the Assessment of Time-
to-event Endpoints in CANcer trials). Ann Oncol 2015;.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , Dowsett M,
Forbes J F, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A,
Coombes R C, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L,
Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C,
Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer:
patient-level meta-analysis of the randomised trials. Lancet 2015;
386:1341-52.
Peters S, von Moos R, Thürlimann B. [Is prescription of a therapy costing
150,000 CHF reasonable?]. Rev Med Suisse 2015; 11:1967-72.
Toi M, Ohno S, Saeki T, Nakamura S, Thürlimann B. For choosing axillary
treatment, and adjuvant hormonal treatment. Breast Cancer 2015;.
14Publikationen
Titel
Wissensch- Leyland-Jones B, Gray K P, Abramovitz M, Bouzyk M, Young B, Long B,
aftlicher Kammler R, Dell'orto P, Biasi M O, Thürlimann B, Harvey V, Neven P,
Artikel/ Arnould L, Maibach R, Price K N, Coates A S, Goldhirsch A, Gelber R D,
Review Pagani O, Viale G, Rae J M, Regan M M, BIG 1-98 Collaborative Group .
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant
letrozole versus tamoxifen or their sequence for early breast cancer.
Breast Cancer Res Treat 2015; 154:543-55.
Hadji P, Coleman R E, Wilson C, Powles T J, Clézardin P, Aapro M, Costa
L, Body J J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D,
Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thürlimann B, Untch M,
Cortes J, Martin M, Albert U S, Conte P F, Ejlertsen B, Bergh J, Kaufmann
M, Holen I. Adjuvant bisphosphonates in early breast cancer: Consensus
guidance for clinical practice from a European Panel. Ann Oncol 2015;.
Leyland-Jones B, Gray K P, Abramovitz M, Bouzyk M, Young B, Long B,
Kammler R, Dell'orto P, Biasi M O, Thürlimann B, Lyng M B, Ditzel H J,
Harvey V J, Neven P, Treilleux I, Rasmussen B B, Maibach R, Price K N,
Coates A S, Goldhirsch A, Pagani O, Viale G, Rae J M, Regan M M.
CYP19A1 polymorphisms and clinical outcomes in postmenopausal
women with hormone receptor-positive breast cancer in the BIG 1-98
trial. Breast Cancer Res Treat 2015; 151:373-84.
Coates A S, Winer E P, Goldhirsch A, Gelber R D, Gnant M, Piccart-
Gebhart M, Thürlimann B, Senn H J, Panel members . -Tailoring
therapies-improving the management of early breast cancer: St Gallen
International Expert Consensus on the Primary Therapy of Early Breast
Cancer 2015. Ann Oncol 2015; 26:1533-46.
15Publikationen
Titel
Wissensch- Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C,
aftlicher Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman
Artikel/ K, Johansson H, Price K N, Gelber R D, Goldhirsch A, Coates A S, Aebi S.
Review Bone mineral density and circulating biomarkers in the BIG 1-98 trial
comparing adjuvant letrozole, tamoxifen and their sequences. Breast
Cancer Res Treat 2014; 144:321-9.
Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-
Marsico J, Diem S, Thürlimann B, cerny t. Off-label use of anticancer
drugs in eastern Switzerland: a population-based prospective cohort
study. Eur J Clin Pharmacol 2014; 70:719-25.
Aebi S, Gelber S, Anderson S J, Láng I, Robidoux A, Martín M, Nortier J W
R, Paterson A H G, Rimawi M F, Cañada J M B, Thürlimann B, Murray E,
Mamounas E P, Geyer C E, Price K N, Coates A S, Gelber R D, Rastogi P,
Wolmark N, Wapnir I L, CALOR investigators . Chemotherapy for isolated
locoregional recurrence of breast cancer (CALOR): a randomised trial.
Lancet Oncol 2014; 15:156-63.
Huober J, Thürlimann B. Bone targeted therapy in breast cancer - an old
concept but still much to do. Breast Care (Basel) 2014; 9:310.
templeton a, Ribi K, Surber C, Sun H, Hsu Schmitz S F, Beyeler M,
Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder R C,
Rochlitz C, von Moos R, Zaman K, Thürlimann B, ruhstaller t, Swiss
Group for Clinical Cancer Research (SAKK) Coordinating Center .
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in
breast cancer patients treated with pegylated liposomal doxorubicin
(SAKK 92/08). Breast 2014; 23:244-9.
knauer m, Thürlimann B. Adjuvant bisphosphonates in breast cancer
treatment. Breast Care (Basel) 2014; 9:319-22.
16Publikationen
Titel
Wissensch- Templeton A J, Thürlimann B, Baumann M, Mark M, Stoll S, Schwizer M,
aftlicher Dietrich D, ruhstaller t. Cross-sectional study of self-reported physical
Artikel/ activity, eating habits and use of complementary medicine in breast
Review cancer survivors. BMC Cancer 2013; 13:153.
Goldhirsch A, Winer E P, Coates A S, Gelber R D, Piccart-Gebhart M,
Thürlimann B, Senn H J, Panel members . Personalizing the treatment of
women with early breast cancer: highlights of the St Gallen International
Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
Ann Oncol 2013; 24:2206-23.
Joerger M, Thürlimann B. Chemotherapy regimens in early breast cancer:
major controversies and future outlook. Expert Rev Anticancer Ther
2013; 13:165-78.
Huober J, Cole B F, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B,
Bonnefoi H, Forbes J F, Neven P, Láng I, Smith I, Wardley A, Price K N,
Goldhirsch A, Coates A S, Colleoni M, Gelber R D, Thürlimann B, BIG 1-98
Collaborative and International Breast Cancer Study Groups . Symptoms
of endocrine treatment and outcome in the BIG 1-98 study. Breast
Cancer Res Treat 2013; 143:159-69.
Zaman K, Thürlimann B, Aebi S. Optimal sequence of tamoxifen and
aromatase inhibitors to prevent bone loss. J Clin Oncol 2013; 31:3440-1.
17Publikationen
Titel
Wissensch- Oakman C, Francis P A, Crown J, Quinaux E, Buyse M, De Azambuja E,
aftlicher Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B,
Artikel/ Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I,
Review Gelber R D, Piccart-Gebhart M, Viale G, Di Leo A. Overall survival benefit
for sequential doxorubicin-docetaxel compared with concurrent
doxorubicin and docetaxel in node-positive breast cancer--8-year results
of the Breast International Group 02-98 phase III trial. Ann Oncol 2013;
24:1203-11.
Regan M M, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R,
Dell'orto P, Biasi M O, Thürlimann B, Lyng M B, Ditzel H J, Neven P,
Debled M, Maibach R, Price K N, Gelber R D, Coates A S, Goldhirsch A,
Rae J M, Viale G, Breast International Group (BIG) 1-98 Collaborative
Group . CYP2D6 genotype and tamoxifen response in postmenopausal
women with endocrine-responsive breast cancer: the breast international
group 1-98 trial. J Natl Cancer Inst 2012; 104:441-51.
Ribi K, Aldridge J, Phillips K A, Thompson A, Harvey V, Thürlimann B,
Cardoso F, Pagani O, Coates A S, Goldhirsch A, Price K N, Gelber R D,
Bernhard J, BIG 1-98 Collaborative Group , International Breast Cancer
Study Group . Subjective cognitive complaints one year after ceasing
adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer
2012; 106:1618-25.
Ewertz M, Gray K P, Regan M M, Ejlertsen B, Price K N, Thürlimann B,
Bonnefoi H, Forbes J F, Paridaens R J, Rabaglio M, Gelber R D, Colleoni M,
Láng I, Smith I E, Coates A S, Goldhirsch A, Mouridsen H T. Obesity and
risk of recurrence or death after adjuvant endocrine therapy with
letrozole or tamoxifen in the breast international group 1-98 trial. J Clin
Oncol 2012; 30:3967-75.
18Publikationen
Titel
Wissensch- Joerger M, Ess S, Dehler S, Savidan A, Bouchardy C, Frick H, Konzelmann
aftlicher I, Thürlimann B. A population-based study on the patterns of use of
Artikel/ different chemotherapy regimens in Swiss patients with early breast
Review cancer. Swiss Med Wkly 2012; 142:w13571.
Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann
I, Probst-Hensch N, Ess S. A population-based study on the
implementation of treatment recommendations for chemotherapy in early
breast cancer. Clin Breast Cancer 2012; 12:102-9.
Huober J, Gelber S, Goldhirsch A, Coates A S, Viale G, oehlschlegel c,
Price K N, Gelber R D, Regan M M, Thürlimann B. Prognosis of medullary
breast cancer: analysis of 13 International Breast Cancer Study Group
(IBCSG) trials. Ann Oncol 2012; 23:2843-51.
Joerger M, Thürlimann B, Savidan A, Frick H, Rageth C, Lütolf U, Vlastos
G, Bouchardy C, Konzelmann I, Bordoni A, Probst-Hensch N, Jundt G, Ess
S. Treatment of breast cancer in the elderly: a prospective, population-
based Swiss study. J Geriatr Oncol 2012; 4:39-47.
Karlsson P, Cole B F, Chua B H, Price K N, Lindtner J, Collins J P, Kovács
A, Thürlimann B, Crivellari D, Castiglione-Gertsch M, Forbes J F, Gelber R
D, Goldhirsch A, Gruber G, International Breast Cancer Study Group .
Patterns and risk factors for locoregional failures after mastectomy for
breast cancer: an International Breast Cancer Study Group report. Ann
Oncol 2012; 23:2852-8.
19Publikationen
Titel
Wissensch- Regan M M, Price K N, Giobbie-Hurder A, Thürlimann B, Gelber R D, for
aftlicher the International Breast Cancer Study Group and BIG 1-98 Collaborative
Artikel/ Group . Interpreting breast international group (BIG) 1-98: a
Review randomized, double-blind, phase III trial comparing letrozole and
tamoxifen as adjuvant endocrine therapy for postmenopausal women
with hormone receptor-positive, early breast cancer. Breast Cancer Res
2011; 13:209.
Colleoni M, Giobbie-Hurder A, Regan M M, Thürlimann B, Mouridsen H,
Mauriac L, Forbes J F, Paridaens R, Láng I, Smith I, Chirgwin J,
Pienkowski T, Wardley A, Price K N, Gelber R D, Coates A S, Goldhirsch A.
Analyses adjusting for selective crossover show improved overall survival
with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J
Clin Oncol 2011; 29:1117-24.
Goldhirsch A, Wood W C, Coates A S, Gelber R D, Thürlimann B, Senn H
J, Panel members . Strategies for subtypes--dealing with the diversity of
breast cancer: highlights of the St. Gallen International Expert Consensus
on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;
22:1736-47.
koeberle d, ruhstaller t, Jost L, Pagani O, Zaman K, von Moos R,
oehlschlegel c, Crowe S, Pilop C, Thürlimann B, Swiss Group for Clinical
Cancer Research (SAKK) . Combination of trastuzumab and letrozole
after resistance to sequential trastuzumab and aromatase inhibitor
monotherapies in patients with estrogen receptor-positive, HER-2-
positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
Endocr Relat Cancer 2011; 18:257-64.
20Publikationen
Titel
Wissensch- Viale G, Regan M M, Dell'orto P, Mastropasqua M G, Maiorano E,
aftlicher Rasmussen B B, Macgrogan G, Forbes J F, Paridaens R J, Colleoni M, Láng
Artikel/ I, Thürlimann B, Mouridsen H, Mauriac L, Gelber R D, Price K N,
Review Goldhirsch A, Gusterson B A, Coates A S, for the BIG 1-98 Collaborative
and International Breast Cancer Study Groups . Which patients benefit
most from adjuvant aromatase inhibitors? Results using a composite
measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol
2011; 22:2201-2207.
Bolla D, Bolla, geb. Wiedemann N, oehlschlegel c, Schoening A, Stickel J,
Thürlimann B, Hornung R. Pseudoangiomatous stromal hyperplasia of
breast in man: a case report. Breast J 2011; 17:311-2.
Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, Konzelmann
I, Probst-Hensch N, Ess S. A Population-Based Study on the
Implementation of Treatment Recommendations for Chemotherapy in
Early Breast Cancer. Clin Breast Cancer 2011;.
Chirgwin J, Sun Z, Smith I, Price K N, Thürlimann B, Ejlertsen B,
Bonnefoi H, Regan M M, Goldhirsch A, Coates A S, BIG 1-98 Collaborative
and International Breast Cancer Study Groups . The advantage of
letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger
postmenopausal women and in those with chemotherapy-induced
menopause. Breast Cancer Res Treat 2011; 131:295-306.
Huober J, Baumann M, Rochlitz C, Aebi S, Güth U, von Moos R, Müller A,
von Rohr L, Widmer I, Thürlimann B. Trastuzumab Treatment beyond
Progression in Advanced Breast Cancer: Patterns of Care in Six Swiss
Breast Cancer Centers. Oncology 2011; 81:160-166.
Mark M, Thürlimann B. Fatal pneumonitis after treatment with pegylated
liposomal doxorubicin in a patient with metastatic breast cancer in
complete remission. Med Oncol 2011;.
21Publikationen
Titel
Wissensch- Regan M M, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B,
aftlicher Mauriac L, Forbes J F, Smith I, Láng I, Wardley A, Rabaglio M, Price K N,
Artikel/ Gelber R D, Coates A S, Thürlimann B, BIG 1-98 Collaborative Group ,
Review International Breast Cancer Study Group (IBCSG) . Assessment of
letrozole and tamoxifen alone and in sequence for postmenopausal
women with steroid hormone receptor-positive breast cancer: the BIG
1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol
2011; 12:1101-8.
Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J,
Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S,
on behalf of the Swiss Group for Clinical Cancer Research (SAKK) . Bone
mineral density in breast cancer patients treated with adjuvant letrozole,
tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study
(SAKK 21/07). Ann Oncol 2011;.
The Scientific Board , Harbeck N, von Minckwitz G, Thürlimann B.
Bisphosphonates in adjuvant treatment of early breast cancer. Crit Rev
Oncol Hematol 2010; 74S1:S1.
Phillips K A, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V,
Thürlimann B, Cardoso F, Pagani O, Coates A S, Goldhirsch A, Price K N,
Gelber R D, Bernhard J. Cognitive function in postmenopausal women
receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG
1-98 randomized trial. Breast 2010; 19:388-95.
Brauchli P, Thürlimann B, Crowe S N, Herrmann R. What is the value of
the 21-gene recurrence score?. J Clin Oncol 2010; 28:e671-2.
Huober J, Thürlimann B. Bone targeted therapy in breast cancer: present
and future. Crit Rev Oncol Hematol 2010; 74S1:S7-S10.
22Publikationen
Titel
Wissensch- Antonov J, Popovici V, Delorenzi M, Wirapati P, Baltzer A, Oberli A,
aftlicher Thürlimann B, Giobbie-Hurder A, Viale G, Altermatt H J, Aebi S, Jaggi R.
Artikel/ Molecular risk assessment of BIG 1-98 participants by expression
Review profiling using RNA from archival tissue. BMC Cancer 2010; 10:37.
von Moos R, Caspar C B, Steiner R, Angst R, Inauen R, Schmieding K,
Thürlimann B. Long-term renal safety profile of ibandronate 6 mg infused
over 15 minutes. Onkologie 2010; 33:447-50.
Huober J, Schoch O, templeton a, Spirig C, Thürlimann B. Interstitial
pneumonitis after treatment with bevacizumab and pegylated liposomal
doxorubicin in a patient with metastatic breast cancer. Chemotherapy
2010; 56:69-70.
Paridaens R J, Gelber S, Cole B F, Gelber R D, Thürlimann B, Price K N,
Holmberg S B, Crivellari D, Coates A S, Goldhirsch A. Adjuvant! Online
estimation of chemotherapy effectiveness when added to ovarian function
suppression plus tamoxifen for premenopausal women with estrogen-
receptor-positive breast cancer. Breast Cancer Res Treat 2010;
123:303-10.
Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lütolf U, Thürlimann B.
Geographic variation in breast cancer care in Switzerland. Cancer
Epidemiol 2010; 34:116-21.
Joerger M, Thürlimann B, Huober J. Small HER2-positive, node-negative
breast cancer: who should receive systemic adjuvant treatment?. Ann
Oncol 2010; 22:17-23.
Hawle H, Hess D, Mueller A, Thürlimann B. Low-Dose Fulvestrant
Maintained Long-Term Complete Remission after Poor Response to
Previous Endocrine Therapies in a Patient with Advanced Breast Cancer.
Case Rep Oncol 2010; 3:131-136.
23Publikationen
Titel
Wissensch- Baumann M, Thürlimann B, ruhstaller t. Brustzentrum Kantonsspital St.
aftlicher Gallen – von der Multidisziplinarität zur patientinnenzentrierten
Artikel/ interdisziplinären Betriebsorganisation. Breast Care 2010; 5:188-191.
Review
Mouridsen H T, Lønning P, Beckmann M W, Blackwell K, Doughty J,
Gligorov J, Llombart-Cussac A, Robidoux A, Thürlimann B, Gnant M. Use
of aromatase inhibitors and bisphosphonates as an anticancer therapy in
postmenopausal breast cancer. Expert Rev Anticancer Ther 2010;
10:1825-1836.
Joerger M, templeton a, koeberle d, Engler H, Riesen W F, Thürlimann B.
Procollagen type I N-propeptide is a predictor of skeletal morbidity in
patients with malignant osteolytic bone disease on bisphosphonates.
Cancer Chemother Pharmacol 2010;.
Ess S, Joerger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, Lütolf
U, Savidan A, Thürlimann B. Predictors of state-of-the-art management
of early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.
Phillips K A, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann
B, Cardoso F, Pagani O, Coates A S, Goldhirsch A, Price K N, Gelber R D,
Bernhard J. Cognitive function in postmenopausal breast cancer patients
one year after completing adjuvant endocrine therapy with letrozole and/
or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat 2010;.
Joerger M, Riesen W F, Thürlimann B. Bevacizumab-associated
hyperlipoproteinemia type IIb in a patient with advanced invasive-ductal
breast cancer. J Oncol Pharm Pract 2010;.
Thürlimann B. [Commentary from the viewpoint of an advocate. "Breast
cancer mortality in organized mammography screening in Denmark--a
comparative Study"]. Praxis (Bern 1994) 2010; 99:1217-8.
24Publikationen
Titel
Wissensch- Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , Correa C,
aftlicher McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L,
Artikel/ Darby S. Overview of the randomized trials of radiotherapy in ductal
Review carcinoma in situ of the breast. J Natl Cancer Inst Monographs 2010;
2010:162-77.
Goldhirsch A, Ingle J N, Gelber R D, Coates A S, Thürlimann B, Senn H J,
Panel members . Thresholds for therapies: highlights of the St Gallen
International Expert Consensus on the primary therapy of early breast
cancer 2009. Ann Oncol 2009; 20:1319-29.
Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price K N, Gelber
R D, Holmberg S B, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey M
F, Murray E, Forbes J F, Coates A S, Goldhirsch A, International Breast
Cancer Study Group . Is adjuvant chemotherapy of benefit for
postmenopausal women who receive endocrine treatment for highly
endocrine-responsive, node-positive breast cancer? International Breast
Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009;
116:491-500.
Thürlimann B, Price K N, Gelber R D, Holmberg S B, Crivellari D, Colleoni
M, Collins J, Forbes J F, Castiglione-Gertsch M, Coates A S, Goldhirsch A.
Is chemotherapy necessary for premenopausal women with lower-risk
node-positive, endocrine responsive breast cancer? 10-year update of
International Breast Cancer Study Group Trial 11-93. Breast Cancer Res
Treat 2009; 113:137-44.
Pagani O, Price K N, Gelber R D, Castiglione-Gertsch M, Holmberg S B,
Lindtner J, Thürlimann B, Collins J, Fey M F, Coates A S, Goldhirsch A,
International Breast Cancer Study Group (IBCSG) . Patterns of
recurrence of early breast cancer according to estrogen receptor status:
a therapeutic target for a quarter of a century. Breast Cancer Res Treat
2009; 117:319-24.
25Publikationen
Titel
Wissensch- templeton a, Thürlimann B, Joerger M. Ixabepilon bei lokal
aftlicher fortgeschrittenem oder metastasiertem Mammakarzinom: Neue
Artikel/ Behandlungsoptionen nach Taxanen und Anthrazyklinen. Schweizer
Review Krebsbulletin 2009;114-117.
Joerger M, Senn H J, Thürlimann B. St. Gallen 2009 recommendations on
the treatment of early breast cancer: consensus and controversy.
magazine of european medical oncology 2009; 2:229-231.
ruhstaller t, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, koeberle
d, Mueller U, Hoefliger M, Hess D, boehme c, Thürlimann B. Breast
cancer patients on endocrine therapy reveal more symptoms when self-
reporting than in pivotal trials: an outcome research study. Oncology
2009; 76:142-8.
BIG 1-98 Collaborative Group , Mouridsen H, Giobbie-Hurder A,
Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J F,
Price K N, Regan M M, Gelber R D, Coates A S. Letrozole therapy alone or
in sequence with tamoxifen in women with breast cancer. NEJM 2009;
361:766-76.
Rabaglio M, Sun Z, Price K N, Castiglione-Gertsch M, Hawle H,
Thürlimann B, Mouridsen H, Campone M, Forbes J F, Paridaens R J,
Colleoni M, Pienkowski T, Nogaret J M, Láng I, Smith I, Gelber R D,
Goldhirsch A, Coates A S, BIG 1-98 Collaborative and International
Breast Cancer Study Groups . Bone fractures among postmenopausal
patients with endocrine-responsive early breast cancer treated with 5
years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009;
20:1489-98.
Huober J, Thürlimann B. Adjuvant! When the new world meets the old
world. The Lancet 2009; 10:1028-9.
26Publikationen
Titel
Wissensch- Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO
aftlicher 2009: What's new in breast cancer therapy?. Breast Care 2009;
Artikel/ 4:268-271.
Review Huober J, Thürlimann B. Polychemotherapy in metastatic breast cancer -
pro. Breast Care 2009; 4:367-372.
Huober J, Thürlimann B. The Role of Combination Chemotherapy in the
Treatment of Patients with Metastatic Breast Cancer. Breast Care (Basel)
2009; 4:367-372.
Ess S, Savidan A, Bouchardy C, Bordoni A, Konzelmann I, Jundt G, Probst
N, Frick H, Thürlimann B. Patterns of care of breast cancer patients in
Switzerland: A population based study : Advisory Board: Bachmann G,
St.Gallen (Public Health), Lütolf U, Zurich (Radio Oncology), Obrist R,
Sion (Medical Oncology), Rageth Ch, Zurich (Breast Surgery), Vlastos G,
Geneva (Breast Surgery), Thürlimann B, St.Gallen (Medical Oncology).
http://www.krebsliga-sg.ch/de/krebsregister/index.cfm 2009;.
Giobbie-Hurder A, Price K N, Gelber R D, International Breast Cancer
Study Group , BIG 1-98 Collaborative Group . Design, conduct, and
analyses of Breast International Group (BIG) 1-98: a randomized,
double-blind, phase-III study comparing letrozole and tamoxifen as
adjuvant endocrine therapy for postmenopausal women with receptor-
positive, early breast cancer. Clin Trials 2009; 6:272-87.
Biganzoli L, Bonnefoi H, Cardoso F, Coleman R, Thürlimann B. ASCO
2009: What's New in Breast Cancer Therapy?. Breast Care (Basel) 2009;
4:268-271.
27Publikationen
Titel
Wissensch- Colleoni M, Sun Z, Martinelli G, Basser R L, Coates A S, Gelber R D,
aftlicher Green M D, Peccatori F, Cinieri S, Aebi S, Viale G, Price K N, Goldhirsch A,
Artikel/ International Breast Cancer Study Group . The effect of endocrine
Review responsiveness on high-risk breast cancer treated with dose-intensive
chemotherapy: results of International Breast Cancer Study Group Trial
15-95 after prolonged follow-up. Ann Oncol 2009; 20:1344-51.
Joerger M, Thürlimann B. Update of the BIG 1-98 Trial: where do we
stand?. Breast 2009; 18 Suppl 3:S78-82.
Jakesz R, Dubsky P, Eidtman H, Schem C, Lang A, Thürlimann B. Neue
Erkenntnisse vom SABCS, Expert Discussion. Breast Care 2009; 4:55-60.
Thürlimann B. Some comments to the Pattern of Care Study. Schweiz.
Krebsbulletin 2009; 3:212-212.
Spirig C, Thürlimann B, Huober J. [New treatment approaches in breast
cancer]. Therapeutische Umschau. Revue thérapeutique 2008;
65:207-10.
Viale G, Giobbie-Hurder A, Regan M M, Coates A S, Mastropasqua M G,
Dell'Orto P, Maiorano E, MacGrogan G, Braye S G, oehlschlegel c, Neven
P, Orosz Z, Olszewski W P, Knox F, Thürlimann B, Price K N, Castiglione-
Gertsch M, Gelber R D, Gusterson B A, Goldhirsch A, Breast International
Group Trial 1-98 . Prognostic and predictive value of centrally reviewed
Ki-67 labeling index in postmenopausal women with endocrine-
responsive breast cancer: results from Breast International Group Trial
1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;
26:5569-75.
Huober J, Thürlimann B. [Adjuvant endocrine therapy in breast cancer].
Therapeutische Umschau. Revue thérapeutique 2008; 65:193-200.
28Publikationen
Titel
Wissensch- Pestalozzi B C, Zahrieh D, Mallon E, Gusterson B A, Price K N, Gelber R D,
aftlicher Holmberg S B, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G,
Artikel/ Castiglione-Gertsch M, Coates A S, Goldhirsch A, International Breast
Review Cancer Study Group . Distinct clinical and prognostic features of
infiltrating lobular carcinoma of the breast: combined results of 15
International Breast Cancer Study Group clinical trials. JCO 2008;
26:3006-14.
Strasser F, Lutz T A, Maeder M T, Thürlimann B, bueche d, Tschöp M,
Kaufmann K, Holst B, Brändle M, Von Moss R, cerny t, Demmer-
Steingruber R. Safety, tolerability and pharmacokinetics of intravenous
ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-
controlled, double-blind, double-crossover study. BJC 2008; 98:300-8.
Greuter S, Schmid F, ruhstaller t, Thürlimann B. Bevacizumab-associated
osteonecrosis of the jaw. Ann Oncol 2008; 19:2091-2.
Gruber G, Cole B F, Castiglione-Gertsch M, Holmberg S B, Lindtner J,
Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey M F,
Gelber R D, Coates A S, Price K N, Goldhirsch A, Viale G, Gusterson B A,
International Breast Cancer Study Group . Extracapsular tumor spread
and the risk of local, axillary and supraclavicular recurrence in node-
positive, premenopausal patients with breast cancer. Ann Oncol 2008;
19:1393-401.
Strasser F, Demmer-Steingruber R, boehme c, Schmitz S F H, Thürlimann
B, cerny t, gillessen s. Prevention of docetaxel- or paclitaxel-associated
taste alterations in cancer patients with oral glutamine: a randomized,
placebo-controlled, double-blind study. The Oncologist 2008; 13:337-46.
29Publikationen
Titel
Wissensch- Aapro M, Abrahamsson P A, Body J J, Coleman R E, Colomer R, Costa L,
aftlicher Crinò L, Dirix L, Gnant M, Gralow J, Hadji P, Hortobagyi G N, Jonat W,
Artikel/ Lipton A, Monnier A, Paterson A H G, Rizzoli R, Saad F, Thürlimann B.
Review Guidance on the use of bisphosphonates in solid tumours:
recommendations of an international expert panel. Ann Oncol 2008;
19:420-32.
von Moos R, Caspar C B, Thürlimann B, angst r, inauen r, Greil R,
Bergstrom B, Schmieding K, Pecherstorfer M. Renal safety profiles of
ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label
study. Ann Oncol 2008; 19:1266-70.
Coates A, Mouridsen H, Thürlimann B, BIG 1-98 Collaborative Group .
Inappropriate ATAC on tamoxifen. The Lancet 2008; 9:315-6.
Bernhard J, Zahrieh D, Zhang J J, Martinelli G, Basser R, Hürny C, Forbes
J F, Aebi S, Yeo W, Thürlimann B, Green M D, Colleoni M, Gelber R D,
Castiglione-Gertsch M, Price K N, Goldhirsch A, Coates A S, International
Breast Cancer Study Group . Quality of life and quality-adjusted survival
(Q-TWiST) in patients receiving dose-intensive or standard dose
chemotherapy for high-risk primary breast cancer. BJC 2008; 98:25-33.
von Moos R, Thürlimann B, Aapro M, Rayson D, Harrold K, Sehouli J,
Scotte F, Lorusso D, Dummer R, Lacouture M E, Lademann J, Hauschild
A. Pegylated liposomal doxorubicin-associated hand-foot syndrome:
recommendations of an international panel of experts. EJO 2008;
44:781-90.
30Publikationen
Titel
Wissensch- Rasmussen B B, Regan M M, Lykkesfeldt A E, Dell'Orto P, Del Curto B,
aftlicher Henriksen K L, Mastropasqua M G, Price K N, Méry E, Lacroix-Triki M,
Artikel/ Braye S, Altermatt H J, Gelber R D, Castiglione-Gertsch M, Goldhirsch A,
Review Gusterson B A, Thürlimann B, Coates A S, Viale G, BIG 1-98 Collaborative
and International Breast Cancer Study Groups . Adjuvant letrozole versus
tamoxifen according to centrally-assessed ERBB2 status for
postmenopausal women with endocrine-responsive early breast cancer:
supplementary results from the BIG 1-98 randomised trial. The Lancet
2008; 9:23-8.
Crivellari D, Sun Z, Coates A S, Price K N, Thürlimann B, Mouridsen H,
Mauriac L, Forbes J F, Paridaens R J, Castiglione-Gertsch M, Gelber R D,
Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith I E,
Chirgwin J H, Goldhirsch A. Letrozole compared with tamoxifen for elderly
patients with endocrine-responsive early breast cancer: the BIG 1-98
trial. JCO 2008; 26:1972-9.
Regan M M, Pagani O, Walley B, Torrisi R, Perez E A, Francis P, Fleming G
F, Price K N, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates A S,
Goldhirsch A, Gelber R D, SOFT/TEXT/PERCHE Steering Committee ,
International Breast Cancer Study Group . Premenopausal endocrine-
responsive early breast cancer: who receives chemotherapy?. Ann Oncol
2008; 19:1231-41.
Mouridsen H, Keshaviah A, Coates A S, Rabaglio M, Castiglione-Gertsch
M, Sun Z, Thürlimann B, Mauriac L, Forbes J F, Paridaens R, Gelber R D,
Colleoni M, Smith I, Price K N, Goldhirsch A. Cardiovascular adverse
events during adjuvant endocrine therapy for early breast cancer using
letrozole or tamoxifen: safety analysis of BIG 1-98 trial. JCO 2007;
25:5715-22.
31Publikationen
Titel
Wissensch- Viale G, Regan M M, Maiorano E, Mastropasqua M G, Dell'Orto P,
aftlicher Rasmussen B B, Raffoul J, Neven P, Orosz Z, Braye S, oehlschlegel c,
Artikel/ Thürlimann B, Gelber R D, Castiglione-Gertsch M, Price K N, Goldhirsch A,
Review Gusterson B A, Coates A S. Prognostic and predictive value of centrally
reviewed expression of estrogen and progesterone receptors in a
randomized trial comparing letrozole and tamoxifen adjuvant therapy for
postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;
25:3846-52.
Goldhirsch A, Wood W C, Gelber R D, Coates A S, Thürlimann B, Senn H
J, 10th St. Gallen conference . Progress and promise: highlights of the
international expert consensus on the primary therapy of early breast
cancer 2007. Ann Oncol 2007; 18:1133-44.
Karlsson P, Cole B F, Price K N, Coates A S, Castiglione-Gertsch M,
Gusterson B A, Murray E, Lindtner J, Collins J P, Holmberg S B, Fey M F,
Thürlimann B, Crivellari D, Forbes J F, Gelber R D, Goldhirsch A, Wallgren
A. The role of the number of uninvolved lymph nodes in predicting
locoregional recurrence in breast cancer. JCO 2007; 25:2019-26.
Thürlimann B. Reducing the risk of early recurrence in hormone-
responsive breast cancer. Ann Oncol 2007; 18 Suppl 8:viii8-17.
ruhstaller t, Thürlimann B, koeberle d, von Moos R. Is surgery still part of
local therapy in patients with locally advanced esophageal carcinoma?.
JCO 2007; 25:4025-6; author reply 4026-7.
Seeholzer N, Thürlimann B, koeberle d, Hess D, Korte W. Combining
chemotherapy and low-molecular-weight heparin for the treatment of
advanced breast cancer: results on clinical response, transforming
growth factor-beta 1 and fibrin monomer in a phase II study. Blood
coagulation & fibrinolysis : an international journal in haemostasis and
thrombosis 2007; 18:415-23.
32Publikationen
Titel
Wissensch- Salzberg M, Thürlimann B, Hasler U, Delmore G, von Rohr A, Thurlimann
aftlicher A, ruhstaller t, Stopatschinskaja S, von Moos R. Pegylated liposomal
Artikel/ doxorubicin (caelyx) in metastatic breast cancer: a community-based
Review observation study. Oncology 2007; 72:147-51.
Ribi K, Bernhard J, Rufibach K, Thürlimann B, von Moos R, ruhstaller t,
Glaus A, Böhme C. Endocrine symptom assessment in women with breast
cancer: what a simple "yes" means. JSCC 2007; 15:1349-56.
Hess D, koeberle d, Thürlimann B, Pagani O, Schonenberger A, Mattmann
S, Rochlitz C, Rauch D, Schuller J C, Ballabeni P, Ribi K, Swiss Group for
Clinical Cancer Research . Capecitabine and vinorelbine as first-line
treatment in elderly patients (> or =65 years) with metastatic breast
cancer. A phase II trial (SAKK 25/99). Oncology 2007; 73:228-37.
Coates A S, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J
F, Paridaens R, Castiglione-Gertsch M, Gelber R D, Colleoni M, Láng I, Del
Mastro L, Smith I, Chirgwin J, Nogaret J M, Pienkowski T, Wardley A,
Jakobsen E H, Price K N, Goldhirsch A. Five years of letrozole compared
with tamoxifen as initial adjuvant therapy for postmenopausal women
with endocrine-responsive early breast cancer: update of study BIG 1-98.
JCO 2007; 25:486-92.
Thürlimann B, koeberle d, Senn H J. Guidelines for the adjuvant
treatment of postmenopausal women with endocrine-responsive breast
cancer: past, present and future recommendations. EJC 2007; 43:46-52.
33Publikationen
Titel
Wissensch- International Breast Cancer Study Group , Colleoni M, Gelber S,
aftlicher Simoncini E, Pagani O, Gelber R D, Price K N, Castiglione-Gertsch M,
Artikel/ Coates A S, Goldhirsch A. Effects of a treatment gap during adjuvant
Review chemotherapy in node-positive breast cancer: results of International
Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Ann Oncol
2007; 18:1177-84.
Kapp U, Fürstenberger G. Die Primärbehandlung des frühen
Mammakarzinoms : Internationale St. Gallen-Konsensus Konferenz 2007.
Schweizer Zeitschrift für Onkologie 2007; 4:6-10.
. Brustzentren in der Schweiz. Schweizer Zeitschrift für Onkologie 2007;
4:22-23.
Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes J F, Thürlimann
B, Paridaens R, Monnier A, Láng I, Wardley A, Nogaret J M, Gelber R D,
Castiglione-Gertsch M, Price K N, Coates A S, Smith I, Viale G, Rabaglio
M, Zabaznyi N, Goldhirsch A, BIG 1-98 Collaborative Group ,
International Breast Cancer Study Group . Predictors of early relapse in
postmenopausal women with hormone receptor-positive breast cancer in
the BIG 1-98 trial. Ann Oncol 2007; 18:859-67.
koeberle d, Thürlimann B. Letrozole as upfront endocrine therapy for
postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Breast Cancer Res Treat 2007; 105 Suppl 1:55-66.
Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins
J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price K N, Pagani O,
Simoncini E, Castiglione Gertsch M, Gelber R D, Coates A S, Goldhirsch A.
CA15-3 and alkaline phosphatase as predictors for breast cancer
recurrence: a combined analysis of seven International Breast Cancer
Study Group trials. Ann Oncol 2007; 18:701-8.
34Publikationen
Titel
Wissensch- Klaeser B, Wiederkehr O, koeberle d, Mueller A, Bubeck B, Thürlimann B.
aftlicher Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron
Artikel/ emission tomography in the pre- and postoperative staging of patients
Review with clinically intermediate or high-risk breast cancer. Ann Oncol 2007;
18:1329-34.
Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber R D,
Forbes J F, Murray E, Collins J, Aebi S, Thürlimann B, Price K N,
Goldhirsch A, Coates A S, International Breast Cancer Study Group Trial
VIII . Adjuvant chemotherapy followed by goserelin compared with either
modality alone: the impact on amenorrhea, hot flashes, and quality of life
in premenopausal patients--the International Breast Cancer Study Group
Trial VIII. JCO 2007; 25:263-70.
Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M,
Dietrich D, Clément P, koeberle d, Goldhirsch A, Thürlimann B. Clinical
benefit of fulvestrant in postmenopausal women with advanced breast
cancer and primary or acquired resistance to aromatase inhibitors: final
results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK
21/00). Ann Oncol 2007; 18:64-9.
Goldhirsch A, Coates A S, Gelber R D, Glick J H, Thürlimann B, Senn H J,
St Gallen Expert Panel Members . First--select the target: better choice of
adjuvant treatments for breast cancer patients. Ann Oncol 2006;
17:1772-6.
Glaus A, boehme c, Thürlimann B, ruhstaller t, Hsu Schmitz S F, Morant
R, Senn H J, von Moos R. Fatigue and menopausal symptoms in women
with breast cancer undergoing hormonal cancer treatment. Ann Oncol
2006; 17:801-6.
35Publikationen
Titel
Wissensch- Fürstenberger G, von Moos R, Lucas R, Thürlimann B, Senn H J,
aftlicher Hamacher J, Boneberg E M. Circulating endothelial cells and angiogenic
Artikel/ serum factors during neoadjuvant chemotherapy of primary breast
Review cancer. BJC 2006; 94:524-31.
ruhstaller t, Roe H, Thürlimann B, Nicoll J J. The multidisciplinary
meeting: An indispensable aid to communication between different
specialities. EJC 2006; 42:2459-62.
Langenegger T, Wahl P, Schiesser D, Thürlimann B. Plasma levels of
tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with
metastatic breast cancer and chronic hemodialysis. Breast Cancer Res
Treat 2006; 100:177-81.
Maschke U, Kränzlin M, Krapf R, Pecherstorfer M, Strebel U, Thürlimann
B. Übersicht Bisphosphonate. Pharmakritik 2006; 28:17-20.
Thürlimann B. Aromatasehemmer in der modernen Brustkrebstheraphie.
Bulletin Leben wie zuvor 2006; 66:19-22.
koeberle d, Thürlimann B. Letrozole as adjuvant endocrine therapy in
postmenopausal women with breast cancer. Expert review of anticancer
therapy 2006; 6:5-10.
koeberle d, Thürlimann B. Adjuvant endocrine therapy in postmenopausal
breast cancer patients. Breast (Edinburgh, Scotland) 2005; 14:446-51.
Breast International Group (BIG) 1-98 Collaborative Group , Thürlimann
B, Keshaviah A, Coates A S, Mouridsen H, Mauriac L, Forbes J F,
Paridaens R, Castiglione-Gertsch M, Gelber R D, Rabaglio M, Smith I,
Wardley A, Wardly A, Price K N, Goldhirsch A. A comparison of letrozole
and tamoxifen in postmenopausal women with early breast cancer. NEJM
2005; 353:2747-57.
36You can also read
